Data investigation

What Sets the Price of Semaglutide: The Routes and the Four Variables

What decides what you pay for semaglutide without coverage: which brand, which strength, what a program counts as a month, and whether your plan refused the drug or one indication.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
11 min read·13 citations

Part of What it costs, and who pays

This article gives no prices. Cash pricing for semaglutide has been rewritten repeatedly over the past year, by the companies that make it and by the federal government, so a number typed into a sentence here would be wrong by the time you read it. What holds still is the set of routes and what decides the arithmetic on each one. Read that here, then take the current figures from our live price tracker and the cheapest semaglutide board, where every one of them carries the date we captured it.

Where the numbers live. Dated per-seller figures sit on the price tracker. Ranked cash options are on /best/cheapest-semaglutide, and the semaglutide without insurance board ranks the same cash sellers on our scores rather than on price. Plan and state coverage rules are in our insurance register. If a figure of ours looks stale, the seller's own checkout wins, and we would like to hear about the gap.

Four things set the number, and the seller is only one of them

Two people paying cash for “semaglutide” on the same day can pay very different amounts without either of them being cheated. Before you compare anything, work out which of these four you are looking at.

What moves a cash figure, independent of which company is quoting it
VariableWhy it moves the number
Which brand, not which moleculeSemaglutide is sold under separate labels for separate conditions, and each label has its own program and its own cash tier. Ozempic's label covers blood-sugar control in adults who have type 2 diabetes, alongside diet and exercise, plus a cardiovascular indication inside that same population.[9] Wegovy's covers cardiovascular risk in people who already have heart disease and carry obesity or excess weight, covers weight reduction and its maintenance, and adds noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval.[8] (For that liver use, our Wegovy for fatty liver board lists the sellers that price the injection.) Asking for “semaglutide” is not specific enough to get a quote.
The strengthNovo Nordisk's own direct pharmacy states plainly that self-pay pricing varies by dose, and lists a different amount for each tablet strength.[1] GLP-1 dosing is designed to climb, so a figure quoted at the strength you start on is a figure for the shortest part of your treatment. The mechanics of that ladder are worth reading before you commit.
Whether the consult and the labs are inside the priceA prescription is required either way. Novo's pharmacy page says so for both its payment paths, and offers to connect you with a prescriber separately.[1] Some sellers fold that visit into one figure and some bill it apart, which changes what a quote means without changing the quote.
What the program calls a monthThis one is almost never read. NovoCare defines one month as one box of four Wegovy pens, one box of one Ozempic pen, or one bottle of thirty tablets. That is a quantity of drug, not an interval on a calendar.[1] Lilly's self-pay program for Zepbound takes the other approach and puts a clock on it: to stay eligible you have to complete the refill purchase within 45 days of your previous delivery.[3]

Route one: buy the approved drug from the company that makes it

Both manufacturers now run their own pharmacy channel, which did not exist when most of the advice on this subject was written. Novo Nordisk sells Wegovy and Ozempic through NovoCare Pharmacy, in pen and tablet form, and the page lets you pick a self-pay path or an insurance path before you see anything else.[1] Lilly sells Zepbound to self-paying patients through LillyDirect under a program it calls the Zepbound Self Pay Journey Program.[3] These are the same FDA-approved products a pharmacy would dispense, sold without a payer in the middle. A prescriber can also sit between you and that channel: Phoenix NP, an Arizona practice, prescribes only brand Wegovy, Zepbound and Foundayo bought from the makers’ own pharmacies, and adds its own fee every 4 weeks on top of the medication price. SkinnyRx lists the Ozempic and Wegovy pens at $1,400 a month with no membership fee, and the Wegovy pill from $248 a month through its membership.

Two things about that channel matter before you use it. Neither is hidden, but both sit in the footnotes, not the headline.

Paying cash can cost you twice

Novo's own explanation of its self-pay option states the trade plainly, so it is quoted here in full.

If you don’t have insurance or elect not to use it, this is your cost. By opting to pay outside of your insurance, any money spent will not count toward your out-of-pocket limits or deductible.
— NovoCare Pharmacy, self-pay explanation, read August 15, 2026

If you have no drug coverage at all, that clause costs you nothing. If you have a plan with a deductible and you decide the cash route is simpler than fighting for coverage, it means a year of payments that leave your deductible exactly where it started.[1] It is a real cost to weigh, though by itself it settles nothing in either direction.

The opening figure and the standing figure are different objects

Novo's savings offer on this channel runs for a stated number of monthly fills, through a stated calendar date, after which a higher standing rate applies, and that standing rate is itself banded by strength.[1] So a quote taken in your first month describes neither what you pay at month six nor what you pay when your dose moves up. Both companies also reserve the right to change or end these programs. Lilly's terms put it about as bluntly as terms are written: the offer may be terminated, rescinded, revoked, or amended at any time, with or without notice.[3] Novo has already flagged the next change. In October 2026 its savings-offer page carries a notice that pricing will be updated after December 31, 2026.[2]

A separate change lands on January 1, 2027, and it is easy to confuse with this one. Novo has announced a cut to the list price of Wegovy, Ozempic and Rybelsus from that date, and says the change does not affect its direct-to-patient self-pay prices.[13] The list price is what a pharmacy bills a plan before rebates. It matters to you if your plan's cost-sharing is tied to it, through a deductible or coinsurance, and it does not reprice the self-pay route.

The manufacturer channel is not the manufacturer. NovoCare's page names CoAssist Pharmacy as a dispensing pharmacy for the service.[1] That is normal, and it is checkable. A program that will not name the pharmacy behind it is missing something these two provide. Look the name up yourself, or find it in our register of pharmacies.

Route two: the federal price channel

There is now a government-run comparison site, trumprx.gov (every TrumpRx GLP-1 price), whose own list carries Wegovy in both pill and pen form, Ozempic and Zepbound at what it labels most-favored-nation prices set against an original price.[4] Medicare's consumer pages point people who fall outside its own GLP-1 program toward it.[5] When we re-checked it on October 17, 2026, the lowest figure it listed for each of those products matched the manufacturer's own starting or introductory self-pay figure for the same product. In practice it is a doorway to the manufacturer programs above, not a separate and cheaper price. We still could not retrieve that site's own frequently-asked-questions answers, so we make no claim about how it handles insurance, pharmacies or refills. Check those against the seller you actually end up buying from, and against our tracker.

Route three: compounded, and what it is now

For three years the cheapest semaglutide in the country was compounded, and that was lawful mainly because the drug sat on FDA's shortage list. That condition is gone. The agency's enforcement discretion ran out on two separate dates: April 22, 2025 for state-licensed pharmacies working under section 503A, then a month later, on May 22, for outsourcing facilities under 503B. At its update of April 1, 2026, the agency recorded that neither semaglutide nor tirzepatide now sits on the shortage list, nor on the bulks list that outsourcing facilities depend on.[7] On April 30, 2026 it proposed not adding semaglutide, tirzepatide or liraglutide to that bulks list, on the ground that no clinical need exists for an outsourcing facility to build them from bulk substance.[11] The comment period closed on July 30, 2026, and as of October 17, 2026 the agency had not issued a final decision.

Compounding a drug for one patient whose documented need an approved product cannot meet remains lawful and remains narrow. What ended was the version of it that funded a cheap national market. For the underlying rule, read which GLP-1s can be compounded; for what to do when your own program closes, read our guide to that situation. If a seller is still shipping compounded semaglutide at volume, the useful question is which basis it claims, and asking it before you enter a card costs nothing.

The pricing questions from route one apply to compounded sellers too, and the answers vary more than the headline prices suggest. Take the dose question. Yes Clinic charges the same price at every dose, and MaxLife sets its price by plan length rather than dose, while Ryze Rx prices each vial by strength, so the bill climbs as the dose does. WellMedRx advertises semaglutide from $49 a month and shows the plan length and billing only at checkout. Northern Colorado Medical publishes a full price list that sets each fill by the total milligrams prescribed, with no membership and no automatic charges.

The opening-versus-standing problem shows up here as well. The “as low as” figures in Vital Step’s ads are first-month rates on six-month plans, and Rejuve Meds posts prices that assume a 12-month plan paid up front. Brello Health sells three-month plans that renew every 11 weeks, so a monthly figure understates what you pay in a year. Kora MD quotes a lower first month for injectable semaglutide than the price that follows it, and its figures differ from page to page. TrimRx’s terms put compounded semaglutide at $199 for the first month and $299 for each month after. Bon Health goes the other way: it bills one month at a time with no membership fee, and prepaying a longer term is optional. Sellers whose price carries no separate membership charge are collected on one board.

A few sellers put the number in front of you before the health questionnaire, which makes comparing them easier. Nu Image Medical does, and sells compounded semaglutide and tirzepatide as weekly injections or rapid-dissolve tablets. Invigor Medical also shows a price first, but labels its plans compounded GLP-1 and GLP-1 + GIP without naming the molecule, which is the moment to ask which drug you are being quoted. System Labs shows its prices up front as well, though its public list carries neither semaglutide nor tirzepatide. Way Better MD posts its prices on each treatment page, including one semaglutide injection price at every dose for people already on a GLP-1, and charges only after a provider approves.

The part people skip: check whether you are actually uninsured for this

“Without insurance” is doing two different jobs in the search box. Sometimes it means no coverage at all. More often it means a plan that has already refused, and those are not the same position, because a refusal is usually specific to an indication rather than to a molecule.

The clearest evidence for that comes from Medicare's own consumer page. Its temporary GLP-1 program lists people with type 2 diabetes among those who are not eligible, and gives the reason in a parenthesis: their Part D plan might cover the drug already.[5] The same logic runs through commercial plans. A plan that excludes weight management may still pay for the diabetes prescription, and the two are separate products carrying separate labels. Ozempic and Mounjaro are approved for blood-sugar control in type 2 diabetes; Wegovy and Zepbound are approved for weight reduction, and Zepbound additionally for moderate to severe obstructive sleep apnea.[8][9][10][12] Which of those your prescriber writes is a clinical decision, not a billing tactic, so raise it with them.

Check two more things before you settle on cash.

  • Medicare's GLP-1 Bridge, if you have Part D. CMS is running a short-term demonstration between July 1, 2026 and December 31, 2027, outside the ordinary Part D machinery for coverage and payment. It covers Foundayo, Wegovy injection and tablets, and the KwikPen formulation of Zepbound only; the single-dose Zepbound vials and pens are excluded.[6] Eligibility turns on age, BMI and a listed comorbidity, and a prescriber has to submit a prior authorization attesting to it.[5][6] The drug list has already been revised once, on April 6, 2026, so check it rather than trusting a summary, including this one.
  • Savings cards, and the sentence that disqualifies most people. They are real, and they are conditional. Novo's enrollment form asks up front whether you are enrolled in any government, state or federally funded medical or prescription benefit program, naming Medicare, Medigap, VA, DOD, TRICARE and Medicaid among the examples.[2] TRICARE members are better off checking their own plan’s GLP-1 rules first. Its self-pay footnotes say the same thing more briefly: government beneficiaries excluded.[1] Lilly's savings-card terms run the other way for one product, requiring enrollment in a commercial drug insurance plan and barring reimbursement claims from any insurer, third party or health savings account.[3] Read the eligibility text before you plan a budget around a card; the free-medicine programs, which run on the opposite insurance rule, are set out in GLP-1 patient assistance programs.
Do not let a price decide your dose. If a strength is priced above what you can pay, that is a conversation for the person who wrote the prescription, not a reason to stretch a vial, skip a week or stay low. We publish the pricing structure so you can raise it with them with the facts in hand.

What to ask before you pay cash

  1. Which brand am I being quoted, and at which strength? A figure without both is not a price.
  2. What does this program define as one month? A box, a bottle, or a calendar month, and is there a refill window that ends my eligibility if I miss it?[1][3]
  3. Is this the introductory figure or the standing one? Ask for the date the introductory period ends and the figure that follows it, in writing.[1]
  4. What happens to this figure when my dose goes up? Get every rung, not the one you start on.[1]
  5. Does anything I pay here count toward my deductible? On a manufacturer self-pay path the answer is no, and the manufacturer says so itself.[1]
  6. Has anyone run a claim yet? If you have a plan, a denial for one indication is not a denial for the drug. Check what your plan and state do in our insurance register.
  7. Is this the approved product or a compounded preparation? If compounded, on what basis, given that the shortage that supported it has ended?[7]

With answers to those seven, you can read a price sheet properly. Then take the current figures from the pages that date them: the price tracker and the cheapest semaglutide board.

Frequently Asked Questions

We deliberately keep prices out of article prose. Cash pricing for this drug changed repeatedly over the past year, at the manufacturers and through a new federal channel, so a figure written into a sentence would be wrong within weeks and could not be kept current in every article. Our numbers live on the tracker and the ranked boards instead, each one stamped with the day it was captured. Use this page to work out which route and which strength you are pricing, then go there for the amount.
Yes, for the approved products. Novo Nordisk sells Wegovy and Ozempic in pen and tablet form through NovoCare Pharmacy on either a self-pay or an insurance path, and Lilly sells Zepbound to self-paying patients through LillyDirect. A prescription is still required on every path. Novo's own page says so for both of its payment routes and offers to connect you with a prescriber separately.
That depends on the brand, the strength and the week, which is why we keep it off this page and on a board that carries dates. What we can tell you is which comparisons are meaningless: a starting-strength figure against a maintenance-strength figure, an introductory offer against a standing rate, and a per-box figure against a per-calendar-month one. Match those three before you compare.
On a manufacturer self-pay program, no, and the manufacturer states it plainly. NovoCare's explanation of its self-pay option says that by opting to pay outside your insurance, any money spent will not count toward your out-of-pocket limits or deductible. If you have a plan with a meaningful deductible, weigh that against the convenience of skipping the coverage fight.
Not necessarily, and this is the step most people skip. Plans generally exclude an indication rather than a molecule, so a refusal for weight management does not always mean a refusal for the same drug prescribed for type 2 diabetes, which is a separate brand with a separate label. Medicare's own consumer page makes the distinction explicitly when it excludes people with type 2 diabetes from its temporary GLP-1 program on the grounds that their Part D plan might cover the drug already. Which prescription is appropriate is a clinical question for your prescriber.
Read the eligibility text before you count on one. Novo's enrollment asks whether you are in any government, state or federally funded medical or prescription program and names Medicare, Medigap, VA, DOD, TRICARE and Medicaid as examples, while some of Lilly's card programs require you to be enrolled in a commercial drug plan and bar reimbursement from any third party. Both companies also reserve the right to change or end these offers, and Lilly's terms say so with or without notice.
The legal ground under the cheap compounded market has gone. Enforcement discretion expired on April 22, 2025 for state-licensed pharmacies and a month later for outsourcing facilities; by the agency's April 1, 2026 update, neither semaglutide nor tirzepatide remained on the shortage list or on the bulks list; and on April 30, 2026 FDA proposed keeping semaglutide, tirzepatide and liraglutide off that bulks list, a proposal still awaiting a final decision in October 2026. Compounding for one patient with a documented individual need is a different and much narrower thing, and it remains available through a prescriber.

References

  1. 1.Novo Nordisk NovoCare® Pharmacy — self-pay and insurance options for Wegovy and Ozempic, program footnotes and terms novocare.com. 2026. https://www.novocare.com/pharmacy.html
  2. 2.Novo Nordisk Wegovy® Savings Offer enrollment — eligibility questions and program conditions novocare.com. 2026. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  3. 3.Eli Lilly and Company Zepbound® Self Pay Journey Program purchase offer and savings card programs — full terms and conditions lilly.com, LillyDirect, terms dated 05/2026. 2026. https://www.lilly.com/lillydirect/medicines/zepbound/self-pay-journey-program-purchase-offer-full-terms-conditions
  4. 4.U.S. Department of Health and Human Services TrumpRx — most-favored-nation medication price listings trumprx.gov. 2026. https://trumprx.gov/
  5. 5.Centers for Medicare & Medicaid Services Weight loss drugs — Medicare coverage and the Medicare GLP-1 Bridge medicare.gov. 2026. https://www.medicare.gov/coverage/weight-loss-drugs
  6. 6.Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge — Information for Part D Plans cms.gov. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
  7. 7.U.S. Food and Drug Administration FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  8. 8.Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection and tablets — prescribing information, section 1 Indications and Usage DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  9. 9.Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, section 1 Indications and Usage DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  10. 10.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, section 1 Indications and Usage DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  11. 11.U.S. Food and Drug Administration FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List FDA Press Announcements, April 30, 2026. 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  12. 12.Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information, section 1 Indications and Usage DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  13. 13.Novo Nordisk Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access PR Newswire, February 24, 2026. 2026. https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html

Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers

Ozempic and Wegovy are the same molecule under different FDA approvals, and Medicaid's drug benefit follows the approved use, which is why the diabetes label clears and the weight-management label is the one a state may refuse under federal law.

12 min read

Does Medicaid Cover Zepbound? The Federal Rule and the Sleep Apnea Indication

Medicaid is run state by state and, under federal law, each program may exclude weight-loss agents, but that exclusion attaches to a use rather than to a drug, which is why Zepbound's obstructive sleep apnea indication changes the conversation.

12 min read

Does Maryland Medicaid Cover Wegovy or Zepbound? Chapter 866 and the Current Rules

Chapter 866 of 2026 lets Maryland Medicaid cover obesity drugs from January 1, 2027, without requiring it, and no election was announced by November 2026. Until then one form covers Wegovy for heart disease or MASH, plus Zepbound for sleep apnea.

7 min read

TRICARE, FEHB and PSHB: Who Covers Wegovy and Zepbound in 2026

TRICARE's weight coverage for Wegovy, Zepbound and Saxenda applies only on Prime, Select and the premium plans, with prior authorization; TRICARE For Life is barred by law. OPM requires every FEHB and PSHB plan to cover a GLP-1, but each plan sets its criteria and tier.

9 min read

Does Georgia Medicaid Cover Wegovy or Zepbound? No, Except a Narrow Teen Route

Georgia's state plan excludes weight-loss drugs, and its November 2026 drug list has no Wegovy or Zepbound row, so adults have no route for weight, heart risk, MASH or sleep apnea. Diabetes coverage is broad, and a cholesterol-linked teen route covers Xenical and Saxenda.

7 min read

South Dakota Medicaid and Wegovy or Zepbound: No Weight-Loss Coverage, Three PA Routes

South Dakota Medicaid lists weight-loss drugs as not covered. Its 2026 OptumRx forms open three routes: Wegovy for heart disease, Wegovy for fatty liver disease with scarring, and Zepbound for sleep apnea. What each form asks, the diabetes split, timelines and appeals.

7 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →